Momenta Pharmaceuticals Announces Fast Track Designation for M281 (nipocalimab) in Hemolytic Disease of the Fetus and Newborn (HDFN)

July 30, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search